{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:54Z","timestamp":1786119294469,"version":"build-2736575974"},"reference-count":34,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004344","name":"Stichting Astma Bestrijding","doi-asserted-by":"publisher","award":["2018\/036"],"award-info":[{"award-number":["2018\/036"]}],"id":[{"id":"10.13039\/501100004344","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009248","name":"Innovatiefonds Zorgverzekeraars","doi-asserted-by":"publisher","award":["B18-110 \/ Dossier 3.580"],"award-info":[{"award-number":["B18-110 \/ Dossier 3.580"]}],"id":[{"id":"10.13039\/501100009248","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2026,3,22]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>One of the most prevalent and impactful symptoms in COPD is persistent dyspnoea, occurring in the majority of patients with advanced COPD. Opioids, mostly morphine, have been investigated and suggested as treatment in palliative care guidelines. However, in recent years multiple trials on morphine for persistent dyspnoea have shown no clinical benefit, and there are concerns regarding adverse events. Transdermal fentanyl has not yet been investigated for this indication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We performed a multicentre, crossover, double-dummy randomised controlled trial, investigating transdermal fentanyl (12\u2005\u03bcg\u00b7h\n                      <jats:sup>\u22121<\/jats:sup>\n                      ), morphine (10\u2005mg\n                      <jats:italic>per os<\/jats:italic>\n                      twice daily) and placebo, during three treatment periods of 2\u2005weeks (including a 3-day washout period). Patients with persistent dyspnoea despite optimal therapy and modified Medical Research Council dyspnoea scale score \u22653 caused by COPD, forced expiratory volume in 1\u2005s (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ) &lt;50% predicted and stable disease were included. The primary end-point was change in mean daily dyspnoea score on a Numeric Rating Scale (NRS). Secondary outcomes were change in worst daily dyspnoea (NRS), health status (Clinical COPD Questionnaire), anxiety (Hospital Anxiety and Depression Scale-Anxiety), hypercapnia (capillary blood gas), mastery (Chronic Respiratory Questionnaire-Mastery) and sleep quality (NRS).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between April 2019 and November 2024, 59 randomisations were performed in 58 participants (mean\u00b1\n                      <jats:sc>sd<\/jats:sc>\n                      69\u00b17\u2005years; 54% female; FEV\n                      <jats:sub>1<\/jats:sub>\n                      33\u00b110% predicted); 37 participants completed the study. The main reasons for study discontinuation were exacerbations (n=13) and side-effects (n=7). There were no significant differences between both fentanyl and morphine compared to placebo for mean and worst dyspnoea, sleep, health status, mastery, anxiety, hypercapnia or side-effects (except for a possible difference in vomiting).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrated no positive effect of transdermal fentanyl nor oral morphine compared to placebo in the treatment of persistent dyspnoea in COPD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.01431-2025","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:20:20Z","timestamp":1780586420000},"page":"2501431","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Fentanyl or morphine for persistent dyspnoea in COPD: a multicentre randomised crossover trial"],"prefix":"10.1183","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2043-1276","authenticated-orcid":false,"given":"Marlies","family":"van Dijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris J.M.","family":"Mooren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"van Beurden-Moeskops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxane","family":"Heller-Baan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander M.","family":"de Hosson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remge M.","family":"Pieterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Yee","family":"Lam-Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Pool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5259-0482","authenticated-orcid":false,"given":"Jan-Willem K.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7705-7927","authenticated-orcid":false,"given":"Huib A.M.","family":"Kerstjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"2026080610551744000_68.2.2501431.1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-1543"},{"key":"2026080610551744000_68.2.2501431.2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/SPC.0000000000000146","article-title":"Psychosocial consequences of living with breathlessness due to advanced disease","volume":"9","author":"Janssen","year":"2015","journal-title":"Curr Opin Support Palliat Care"},{"key":"2026080610551744000_68.2.2501431.3","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00322-2019"},{"key":"2026080610551744000_68.2.2501431.4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.523"},{"key":"2026080610551744000_68.2.2501431.5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.286.6366.675"},{"key":"2026080610551744000_68.2.2501431.6","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.6.9711061"},{"key":"2026080610551744000_68.2.2501431.7","unstructured":"Richtlijnendatabase . Palliatieve zorg bij COPD. [Palliative care for COPD.] 2021. https:\/\/richtlijnendatabase.nl\/richtlijn\/palliatieve_zorg_bij_copd\/startpagina_-_palliatieve_zorg_bij_copd.html Date last accessed: 27 May 2025."},{"key":"2026080610551744000_68.2.2501431.8","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.1998.16.4.1588","article-title":"Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine","volume":"16","author":"Payne","year":"1998","journal-title":"J Clin Oncol"},{"key":"2026080610551744000_68.2.2501431.9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12890-021-01647-8","article-title":"Opioids in patients with COPD and refractory dyspnea: literature review and design of a multicenter double blind study of low dosed morphine and fentanyl (MoreFoRCOPD)","volume":"21","author":"van Dijk","year":"2021","journal-title":"BMC Pulm Med"},{"key":"2026080610551744000_68.2.2501431.10","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4037\/ajcc1998.7.3.200","article-title":"Validity of the numeric rating scale as a measure of dyspnea","volume":"7","author":"Gift","year":"1998","journal-title":"Am J Crit Care"},{"key":"2026080610551744000_68.2.2501431.11","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-13"},{"key":"2026080610551744000_68.2.2501431.12","doi-asserted-by":"publisher","DOI":"10.1136\/thx.49.5.465"},{"key":"2026080610551744000_68.2.2501431.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"2026080610551744000_68.2.2501431.14","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00034805"},{"key":"2026080610551744000_68.2.2501431.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2013.01.011"},{"key":"2026080610551744000_68.2.2501431.16","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2019-213681"},{"key":"2026080610551744000_68.2.2501431.17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.20206"},{"key":"2026080610551744000_68.2.2501431.18","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpainsymman.2019.10.017","article-title":"Controlled-release oxycodone vs. placebo in the treatment of chronic breathlessness \u2013 a multisite randomized placebo controlled trial","volume":"59","author":"Ferreira","year":"2020","journal-title":"J Pain Symptom Manage"},{"key":"2026080610551744000_68.2.2501431.19","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1001\/jamainternmed.2020.3134","article-title":"Effect of sustained-release morphine for refractory breathlessness in chronic obstructive pulmonary disease on health status: a randomized clinical trial","volume":"180","author":"Verberkt","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2026080610551744000_68.2.2501431.20","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S2213-2600(25)00205-X","article-title":"Morphine for chronic breathlessness (MABEL) in the UK: a multi-site, parallel-group, dose titration, double-blind, randomised, placebo-controlled trial","volume":"13","author":"Johnson","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026080610551744000_68.2.2501431.21","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0265-2023"},{"key":"2026080610551744000_68.2.2501431.22","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201501-034OC"},{"key":"2026080610551744000_68.2.2501431.23","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1177\/02692163231194838","article-title":"Effectiveness and safety of opioids on breathlessness and exercise endurance in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomised controlled trials","volume":"37","author":"Liu","year":"2023","journal-title":"Palliat Med"},{"key":"2026080610551744000_68.2.2501431.24","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/02692163241234212","article-title":"Re: Liu et al., Effectiveness and safety of opioids on breathlessness and exercise endurance in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomised controlled trials","volume":"38","author":"Johnson","year":"2024","journal-title":"Palliat Med"},{"key":"2026080610551744000_68.2.2501431.25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006818"},{"key":"2026080610551744000_68.2.2501431.26","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00275-2019"},{"key":"2026080610551744000_68.2.2501431.27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2017-000235"},{"key":"2026080610551744000_68.2.2501431.28","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S2213-2600(24)00187-5","article-title":"Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial","volume":"12","author":"Higginson","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026080610551744000_68.2.2501431.29","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01270-2018"},{"key":"2026080610551744000_68.2.2501431.30","first-page":"CD007354","article-title":"Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults","volume":"10","author":"Simon","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080610551744000_68.2.2501431.31","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0012-2024"},{"key":"2026080610551744000_68.2.2501431.32","doi-asserted-by":"publisher","DOI":"10.1177\/0269216319835393"},{"key":"2026080610551744000_68.2.2501431.33","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S2213-2600(14)70226-7","article-title":"An integrated palliative and respiratory care service for patients with advanced disease and refractory breathlessness: a randomised controlled trial","volume":"2","author":"Higginson","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2026080610551744000_68.2.2501431.34","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/15412555.2022.2099821","article-title":"Filling the gap: a feasibility study of a COPD-specific breathlessness service","volume":"19","author":"Mooren","year":"2022","journal-title":"COPD"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01431-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:55:28Z","timestamp":1786038928000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01431-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,8,6]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1183\/13993003.01431-2025"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01431-2025","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]}}}